Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2022
![](/report_cover/8047/glucagon-like-peptide-1-receptor-agonists-pipeline-insight-2021_en.gif)
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Glucagon-Like Peptide 1 Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glucagon-Like Peptide 1 Receptor Agonists: Overview
The human Glucagon-Like Peptide 1 Receptor (GLP-1) receptor is located on chromosome 6 (6p21). The GLP-1 receptor sequence contains a large hydrophilic extracellular domain and seven hydrophobic transmembrane domains. Glucagon-like peptide-1 amide (GLP-1) is a 30-residue peptide hormone released from intestinal L cells following nutrient consumption. It potentiates the glucose-induced secretion of insulin from pancreatic beta cells, increases insulin expression, inhibits beta-cell apoptosis, promotes beta-cell neogenesis, reduces glucagon secretion, delays gastric emptying, promotes satiety and increases peripheral glucose disposal. These multiple physiological effects make it an attractive candidate for type 2 diabetes therapy. Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity.
Report Highlights
This segment of the Glucagon-Like Peptide 1 Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucagon-Like Peptide 1 Receptor Agonists Emerging Drugs
Further product details are provided in the report……..
Glucagon-Like Peptide 1 Receptor Agonists: Therapeutic Assessment
This segment of the report provides insights about the different Glucagon-Like Peptide 1 Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:
Glucagon-Like Peptide 1 Receptor Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glucagon-Like Peptide 1 Receptor Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucagon-Like Peptide 1 Receptor Agonists drugs.
Glucagon-Like Peptide 1 Receptor Agonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Glucagon-Like Peptide 1 Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Glucagon-Like Peptide 1 Receptor Agonists: Overview
The human Glucagon-Like Peptide 1 Receptor (GLP-1) receptor is located on chromosome 6 (6p21). The GLP-1 receptor sequence contains a large hydrophilic extracellular domain and seven hydrophobic transmembrane domains. Glucagon-like peptide-1 amide (GLP-1) is a 30-residue peptide hormone released from intestinal L cells following nutrient consumption. It potentiates the glucose-induced secretion of insulin from pancreatic beta cells, increases insulin expression, inhibits beta-cell apoptosis, promotes beta-cell neogenesis, reduces glucagon secretion, delays gastric emptying, promotes satiety and increases peripheral glucose disposal. These multiple physiological effects make it an attractive candidate for type 2 diabetes therapy. Glucagon-like peptide-1 agonists are a class of medications utilized in the treatment of type 2 diabetes and obesity.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Glucagon-Like Peptide 1 Receptor Agonists R&D. The therapies under development are focused on novel approaches for Glucagon-Like Peptide 1 Receptor Agonists.
This segment of the Glucagon-Like Peptide 1 Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glucagon-Like Peptide 1 Receptor Agonists Emerging Drugs
- IBI-362: Innovent Biologics
- Tirzepatide: Eli Lilly and Company
Further product details are provided in the report……..
Glucagon-Like Peptide 1 Receptor Agonists: Therapeutic Assessment
This segment of the report provides insights about the different Glucagon-Like Peptide 1 Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Glucagon-Like Peptide 1 Receptor Agonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Glucagon-Like Peptide 1 Receptor Agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Glucagon-Like Peptide 1 Receptor Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glucagon-Like Peptide 1 Receptor Agonists drugs.
Glucagon-Like Peptide 1 Receptor Agonists Report Insights
- Glucagon-Like Peptide 1 Receptor Agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Glucagon-Like Peptide 1 Receptor Agonists drugs?
- How many Glucagon-Like Peptide 1 Receptor Agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Glucagon-Like Peptide 1 Receptor Agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glucagon-Like Peptide 1 Receptor Agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glucagon-Like Peptide 1 Receptor Agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eli Lilly and Company
- Innovent Biologics
- Novo Nordisk
- AstraZeneca
- Biolingus
- D and D Pharmatech
- Terns Pharmaceuticals
- i2O Therapeutics
- Tirzepatide
- IBI-362
- Semaglutide subcutaneous
- Exenatide
- Liraglutide biobetter
- Exenatide/insulin sublingual
- DD-02
- GLP-1R agonist therapeutic
- GLP1 analogs
Introduction
Executive Summary
Glucagon-Like Peptide 1 Receptor Agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glucagon-Like Peptide 1 Receptor Agonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glucagon-Like Peptide 1 Receptor Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glucagon-Like Peptide 1 Receptor Agonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tirzepatide: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IBI-362: Innovent Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Exenatide/insulin sublingual: Biolingus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glucagon-Like Peptide 1 Receptor Agonists Key Companies
Glucagon-Like Peptide 1 Receptor Agonists Key Products
Glucagon-Like Peptide 1 Receptor Agonists- Unmet Needs
Glucagon-Like Peptide 1 Receptor Agonists- Market Drivers and Barriers
Glucagon-Like Peptide 1 Receptor Agonists- Future Perspectives and Conclusion
Glucagon-Like Peptide 1 Receptor Agonists Analyst Views
Glucagon-Like Peptide 1 Receptor Agonists Key Companies
Appendix
Executive Summary
Glucagon-Like Peptide 1 Receptor Agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Glucagon-Like Peptide 1 Receptor Agonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Glucagon-Like Peptide 1 Receptor Agonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Glucagon-Like Peptide 1 Receptor Agonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Tirzepatide: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IBI-362: Innovent Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Exenatide/insulin sublingual: Biolingus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Glucagon-Like Peptide 1 Receptor Agonists Key Companies
Glucagon-Like Peptide 1 Receptor Agonists Key Products
Glucagon-Like Peptide 1 Receptor Agonists- Unmet Needs
Glucagon-Like Peptide 1 Receptor Agonists- Market Drivers and Barriers
Glucagon-Like Peptide 1 Receptor Agonists- Future Perspectives and Conclusion
Glucagon-Like Peptide 1 Receptor Agonists Analyst Views
Glucagon-Like Peptide 1 Receptor Agonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Glucagon-Like Peptide 1 Receptor Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products